Table 1.
Baseline Characteristics
| ICI Standard Dose(N = 88) | ICI extended Interval Dose(N = 117) | P Value | |
|---|---|---|---|
| Sex - no. (%) | |||
| Male | 53 (60.2%) | 69 (59.0%) | .97 |
| Female | 35 (39.8%) | 48 (41.0%) | |
| Age at start ICI - years | |||
| Mean (SD) | 66.3 (8.81) | 64.8 (10.0) | .28 |
| Median [Min, Max] | 67.0 [35.0, 82.0] | 66.0 [43.0, 87.0] | |
| ECOG performance-status - no. (%) | |||
| 0 | 32 (36.4%) | 54 (46.2%) | .21 |
| 1 | 47 (53.4%) | 57 (48.7%) | |
| 2 | 9 (10.2%) | 6 (5.1%) | |
| NSCLC subtype - no. (%) | |||
| Squamous cell carcinoma | 29 (33.0%) | 44 (37.6%) | .9 |
| Non-squamous cell carcinoma | 54 (61.4%) | 66 (56.4%) | |
| Mixed type (Sq/Nsq) | 1 (1.1%) | 1 (0.9%) | |
| NSCLC NOS | 4 (4.5%) | 6 (5.1%) | |
| Mutation - no. (%) | |||
| No mutation | 53 (60.2%) | 86 (73.5%) | .26 |
| BRAF | 3 (3.4%) | 3 (2.6%) | |
| MET | 0 (0%) | 1 (0.9%) | |
| KRAS | 29 (33.0%) | 24 (20.5%) | |
| Other | 3 (3.4%) | 3 (2.6%) | |
| PD-L1 - no. (%) | |||
| 0 | 31 (35.2%) | 24 (20.5%) | .17 |
| 1-49% | 17 (19.3%) | 27 (23.1%) | |
| ≥ 50% | 33 (37.5%) | 43 (36.8%) | |
| Missing | 7 (8.0%) | 23 (19.7%) | |
| Treatment | |||
| Pembrolizumab mono | 30 (34.1%) | 35 (29.9%) | .0013 |
| Pembrolizumab + chemo | 11 (12.5%) | 15 (12.8%) | |
| Nivolumab mono | 30 (34.1%) | 18 (15.4%) | |
| Durvalumab adjuvant | 17 (19.3%) | 49 (41.9%) | |
| Line of treatment | |||
| 1st line | 41 (46.6%) | 48 (41.0%) | .0025 |
| 2nd line | 29 (33.0%) | 19 (16.2%) | |
| 3rd line | 1 (1.1%) | 1 (0.9%) | |
| Adjuvant | 17 (19.3%) | 49 (41.9%) |
* P-value ≤ .05 considered statistically significant. N, number of patients.